Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells

Molecular Pharmacology

Volumn 73, Issue 6, 2008, Pages 1679-1687

  Serra, Jordi M ^a,b   Gutiérrez, Antonio ^a,b   Alemany, Regina ^b   Navarro, María ^a   Ros, Teresa ^b   Saus, Carlos ^a   Ginés, Jordi ^a   Sampol, Antonia ^a   Amat, Juan Carlos ^a   Serra Moisés, Lorenzo ^b   Martín, Javier ^a,b   Galmés, Antonio ^a   Vögler, Oliver ^b   Besalduch, Joan ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTIMETABOLITE; GEMCITABINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; GROWTH DISORDER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE C MYC; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; METHOTREXATE; TRANSCRIPTION FACTORS;

EID: 44249110721     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.043372     Document Type: Article

References (29)

1. Betz C, Papadopoulos T, Buchwald J, Dammrich J, and Muller-Hermelink HK (1995) Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 55:4283-4286.
2. Bierau J, van Gennip AH, Rutger Meinsma RL, Caron HN, van Kuilenburg ABP (2006) Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. Cancer Chemother Pharmacol 57:105-113.
3. Broers JL, Jensen SM, Travis WD, Pass H, Whitsett JA, Singh G, Katyal SL, Gazdar AF, Minna JD, and Linnoila RI (1992) Expression of surfactant associated protein-A and Clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab Invest 66:337-346.
4. Chang TH and Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60:1129-1138.
5. Chen JP, Chen L, Leek J, and Lin C (2006) Antisense c-myc fragments induce normal differentiation cycles in HL-60 cells. Eur J Clin Invest 36:49-57.
6. Chu E, Takechi T, Jones KL, Voeller DM, Copur SM, Maley GF, Maley F, Segal S, and Allegra CJ (1995) Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol 15:179-185.
7. d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, Yu IR, Luketich JD (2007) Chemotherapy resistance and oncogene expression in nonsmall cell lung cancer. J Thorac Cardiovasc Surg 133:352-359.
8. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, and Kuzumaki N (1998) Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58:322-327.
9. Gazzeri S, Brambilla E, Jacrot M, Chauvin C, Benabid AL, and Brambilla C (1991) Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res 51:2566-2571.
10. Henriksson M and Luscher B (1996) Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 68:109-182.
11. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, and Beppu T (1994) Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214:189-197.
12. Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschi H, and Szabo E (1998) MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 58:5582-5589.
13. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, and Standiford TJ (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:100-108.
14. Kimura E, Nishimura K, Sakata K, Oga S, Kashiwagi K, and Igarashi K (2004) Methotrexate differentially affects growth of suspension and adherent cells. Int J Biochem Cell Biol 36:814-825.
15. Kohno M and Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211.
16. Lorenz J, Friedberg T, Paulus R, Oesch F, and Ferlinz R (1994) Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance. Clin Investig 72:156-163.
17. Lutterbach B and Hann SR (1994) Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510-5522.
18. Maghfoor I and Perry MC (2005) Lung cancer. Ann Saudi Med 25:1-12.
19. Marchal JA, Rodriguez-Serrano F, Campos J, Madeddu R, Boulaiz H, Martinez-Amat A, Carrillo E, Caba O, Prados JC, Velez C, et al. (2006) Differentiation: an encouraging approach to anticancer therapy. Ital J Anat Embryol 111:45-64.
20. Martínez J, Gutierrez A, Casas J, Llado V, Lopez-Bellan A, Besalduch J, Dopazo A, and Escriba PV (2005a) The repression of E2F-1 is critical for the activity of Minerval against cancer. J Pharmacol Exp Ther 315:466-474.
21. Martínez J, Vogler O, Casas J, Barcelo F, Alemany R, Prades J, Nagy T, Baamonde C, Kasprzyk PG, Teres S, et al. (2005b) Membrane structure modulation, protein kinase C alpha activation, and anticancer activity of minerval. Mol Pharmacol 67:531-540.
22. McGuire JJ (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9:2593-2613.
23. Moran CA (2006) Pulmonary adenocarcinoma: the expanding spectrum of histologic variants. Arch Pathol Lab Med 130:958-962.
24. Nishimoto S and Nishida E (2006) MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7:782-786.
25. Seger R and Krebs EG (1995) The MAPK signaling cascade. FASEB J 9:726-735.
26. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117.
27. Singh R, Fouladi-Nashta AA, Li D, Halliday N, Barrett DA, and Sinclair KD (2006) Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem 99:146-155.
28. Spira AI and Carducci MA (2003) Differentiation therapy. Curr Opin Pharmacol 3:338-343.
29. Vita M and Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16:318-330.